ABEONA THERAPEUTICS INC. (ABEO)
ABEONA THERAPEUTICS INC. (ABEO)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Other current liabilities | NaN | -23 | 0 | -62 |
| Net loss | -17,075 | -20,460 | -5,161 | 96,804 |
| Depreciation and amortization | 690 | 863 | 608 | 1,078 |
| Gain on disposal of property and equipment | NaN | 0 | NaN | 0 |
| Stock-based compensation expense | 2,957 | 2,559 | 2,689 | 5,531 |
| Change in fair value of warrant liabilities | -5,386 | -1,522 | -2,760 | -1,857 |
| Accretion and interest on short-term investments | -13 | -687 | 88 | -290 |
| Amortization of right-of-use lease assets | 179 | 229 | 280 | 505 |
| Non-cash interest | 274 | 284 | 270 | 598 |
| Gain from sale of priority review voucher | NaN | 0 | 0 | 152,366 |
| Accounts receivable | 53 | 6,147 | NaN | NaN |
| Inventory | 561 | 643 | 2,164 | 2,686 |
| Other receivables | -59 | -1,048 | -14 | -22 |
| Prepaid expenses and other current assets | 657 | -915 | 119 | 947 |
| Other assets | 46 | 240 | 203 | 242 |
| Accounts payable and accrued expenses | -7,315 | 4,238 | 1,001 | 1,301 |
| Lease liabilities | -182 | 472 | -381 | -667 |
| Change in payable to licensor | 7,000 | 0 | NaN | NaN |
| Deferred revenue | 425 | NaN | NaN | NaN |
| Accrued taxes and other current liabilities | -126 | -213 | -15,173 | 15,512 |
| Net cash used in operating activities | -19,804 | -17,953 | -21,187 | -37,186 |
| Proceeds from disposal of property and equipment | NaN | 0 | NaN | 0 |
| Proceeds from sale of priority review voucher, net of transaction costs of 2.6 million | NaN | 0 | 0 | 152,366 |
| Capital expenditures | 935 | 1,153 | 2,520 | 4,302 |
| Purchases of short-term investments | 19,000 | 37,784 | 100,351 | 68,499 |
| Proceeds from maturities of short-term investments | 24,898 | 48,491 | 38,244 | 80,536 |
| Net cash provided by investing activities | 4,963 | 9,554 | -64,627 | 160,101 |
| Proceeds from underwritten sales of common stock, net of issuance costs | NaN | 0 | NaN | 0 |
| Proceeds from issuance of long-term debt | NaN | 0 | NaN | 0 |
| Payment of debt issuance costs | NaN | 0 | NaN | 0 |
| Proceeds from atm sales of common stock, net of issuance costs | NaN | 0 | 0 | 17,300 |
| Payments related to net settlement of restricted share awards | NaN | 0 | 0 | -37 |
| Proceeds from exercise of warrants | NaN | 3,614 | 5,163 | NaN |
| Payments of long-term debt | 2,222 | NaN | NaN | NaN |
| Net cash (used in) provided by financing activities | -2,222 | 3,614 | 5,163 | 17,263 |
| Net decrease in cash, cash equivalents and restricted cash | -17,063 | -4,785 | -80,651 | 140,178 |
| Cash, cash equivalents and restricted cash at beginning of period | 83,222 | NaN | 23,695 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 61,374 | NaN | 83,222 | NaN |